Business
ImmuPharma : FINAL RESULTS for the twelve months ended 31 December 2025
ImmuPharma : FINAL RESULTS for the twelve months ended 31 December
About this update from Immupharma Plc
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its Final Results for the twelve months ended 31 December 2025 (the "Period"). Key Highlights (including post Period review) Financials Loss for the Period of £1.8m (2024: £2.5m) Research and development expenses of £1.3m (2024: £1.2m) Administrative expenses of £1.0m (2024: £1.0m) Share based expense of £0.1m (2024: £0.09m) Cash balance of £1.4m at 31 December 2025 (31 December 2024: £0.2m) Lanstead derivative financial asset of £nil (2024: £0.2m) Basic and diluted loss per share of 0.37p (2024: 0.60p) On 7 April 2026, a £6.47 million fundraise at 6p was completed, comprising: £6m subscription through Lanstead Capital; plus WRAP Retail Offer of £0.47m Portfolio P140 technology platform Continued progress with the Company's P140 autoimmune technology platform, which remains ImmuPharma's lead asset and core value driver As highlighted in the patent application submission in September 2025, P140 is being developed alongside the Type M companion diagnostic platform, designed to identify "super-responder" patients and enable a precision medicine approach in autoimmune diseases The recent P140 scientific update in April 2026, further strengthened the program's foundations, highlighting the first Combined Search and Examination Report for the UK patent application, supported by new study data A scientific manuscript is now in preparation for submission to a peer-reviewed journal These developments enhance the credibility and long-term commercial potential of P140 Kapiglucagon Kapiglucagon has been accelerated as a key earlier-stage strategic asset in the Company's portfolio, expanding ImmuPharma's peptide-based innovation into metabolic disease and Type 1 diabetes Kapiglucagon is a proprietary glucagon prodrug designed to overcome the formulation instability of native glucagon, with potential application in dual-hormone artificial pancreas systems and other glucagon-based therapeutic applications The Company has initiated IND-enabling activities for Kapiglucagon, including preparation for a pre-IND meeting with the FDA and evaluation of a 505(b)(2) regulatory pathway, subject to FDA confirmation Partnering opportunities Active discussions continue with a number of potential global commercial partners for P140, with the Company...